Universal STAR-T Cell
Phase 1
Universal STAR-T Cell is one of 47 therapeutic programs targeting Generalized Myasthenia Gravis. It is currently in Phase 1.
3
Indications
2
Total Trials
2
Active Trials
46
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
43 competitors in Iga Nephropathy
#DrugCompanyPhaseTrials
1Cellcept
RocheApproved
Rituxan
RocheApproved
Lorelco
SanofiApproved
Fabhalta
NovartisApproved
Tekturna
Tibotec Pharmaceuticals, IrelandApproved
Velcade
SShilpa Grover, MD, MPH
Approved
Kerendia
BayerPhase 3
Farxiga
AstraZenecaPhase 3
Filspari
TTravere Therapeutics, Inc.
Phase 3
Vanrafia
NovartisPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
IgA Nephropathy (IgAN)1 trial
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Universal STAR-T Cell. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]
- Company
- DDaishi Tian